Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Marimed (MRMD) EBIAT (2016 - 2025)

Marimed has reported EBIAT over the past 15 years, most recently at -$4.7 million for Q4 2025.

  • Quarterly EBIAT rose 43.75% to -$4.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$14.5 million through Dec 2025, down 16.09% year-over-year, with the annual reading at -$14.5 million for FY2025, 16.18% down from the prior year.
  • EBIAT was -$4.7 million for Q4 2025 at Marimed, down from -$2.9 million in the prior quarter.
  • Over five years, EBIAT peaked at $7.5 million in Q2 2021 and troughed at -$10.2 million in Q4 2023.
  • The 5-year median for EBIAT is -$1.2 million (2024), against an average of -$1.1 million.
  • Year-over-year, EBIAT surged 717.2% in 2021 and then tumbled 320.5% in 2023.
  • A 5-year view of EBIAT shows it stood at -$6.4 million in 2021, then skyrocketed by 172.04% to $4.6 million in 2022, then plummeted by 320.5% to -$10.2 million in 2023, then increased by 18.32% to -$8.3 million in 2024, then soared by 43.75% to -$4.7 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's EBIAT are -$4.7 million (Q4 2025), -$2.9 million (Q3 2025), and -$1.4 million (Q2 2025).